admin

The past year has been the most important in Emergent BioSolutions’ history. We’ve had the honor of helping our country address Covid-19, manufacturing vaccines in a way few companies can. Deploying longstanding pandemic preparedness capabilities to shorten timelines and ramp up large-scale manufacturing, we can now make more than a billion doses of Covid-19 vaccine a year.

GAITHERSBURG, Md., March 15, 2021 /PRNewswire/ — US-based biotech company VLP Therapeutics, Inc. (VLPT) announced that it has named Ms. Miwa Toyoda, formerly a venture capitalist specialized in pharma and biotech at JAFCO Group Co., Ltd., as chief business officer, effective March 15, in a bid to accelerate its vaccine research and development projects and expand the portfolio.

SIBF welcomes new members.  See the list here.

This free webinar will feature a fireside chat-style conversation with Dr. Robert Scharpf (Delfi Diagnostics) and Dr. Christie Bergerson (Exponent). Drs. Scharpf and Bergerson will discuss how machine learning and artificial intelligence are impacting biomedical engineering and the wider world of human health.

Rich Bendis (BioHealth Innovation/BioTalk podcast) will facilitate the discussion. View the speaker bios for more information.

The American College of Cardiology is hosting its first Innovation Showcase in partnership with the National Heart, Lung, and Blood Institute (NHLBI).   They have selected six healthcare start-up companies to present. Each presentation will end with a brief Q&A with our panelists, including BHI Entrepreneurs-in-Residence Renee Arnold, Luis Gutierrez, and Kwame Ulmer.  Immediately following the showcase, audience members will have an opportunity to attend breakout sessions with each company and representatives from the NHLBI.   Full details (schedule, presenting companies, registration, etc.) are available at: https://www.acc.org/InnovationShowcase.  

Marina Massingham, CEO, Aifred Health, and Laurent Waessa, Senior Business Development Advisor, Québec Government Office in New York, join BioTalk to discuss their backgrounds, Ecosystems for Entrepreneurs, and how Quebec can find partnerships in the BioHealth Capital Region

Listen via Apple http://apple.co/3lfW7q5, Google http://bit.ly/3qJm2HP, Spotify http://spoti.fi/30LaoSc, and TuneIn http://bit.ly/30JHq4Z.

When the pandemic hit in full force last March, healthcare organizations had to pivot overnight. What was once impossible became necessary, and what was once unlikely became an everyday occurrence. While this disruption came with growing pains — health organizations faced supply, staff and support shortages for months on end — the World Economic Forum notes that “the industry’s response has vividly demonstrated its resilience and ability to bring innovations to market quickly.”

Novavax reported on March 11 that its COVID-19 vaccine is 96% efficacious in reducing mild, moderate or severe disease. The Maryland-based company joins the handful of manufacturers that have reported encouraging data on a COVID-19 vaccine; three, Pfizer-BioNTech, Moderna and Johnson & Johnson’s Janssen Pharmaceuticals, have already received emergency use authorization for their shots from the U.S. Food and Drug Administration.

The advancement of children’s medical devices in the U.S. continues to significantly lag behind adult devices for many reasons. A dedicated group of public and private sector healthcare leaders are working together to change that trend. In culmination of its first stage of work, the System of Hospitals for Innovation in Pediatrics – Medical Devices (SHIP-MD) initiative recently held a dynamic 3-day public workshop to further develop this groundbreaking public-private partnership, which is currently in its pre-consortium/conceptual phase.